Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX)

Critical Care Medicine

Volumn 43, Issue 1, 2015, Pages 57-64

  Vincent, Jean Louis ^a   Privalle, Christopher T ^b   Singer, Mervyn ^c   Lorente, José A ^d   Boehm, Erwin ^e   Meier Hellmann, Andreas ^f   Darius, Harald ^g   Ferrer, Ricard ^h,i   Sirvent, Josep Maria ^i,j   Marx, Gernot ^k   De Angelo, Joseph ^b  

^a ERASME HOSPITAL   (Belgium)

^b Apex Bioscience   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^e Curacyte AG   (Germany)

^f HELIOS KLINIKUM ERFURT   (Germany)

^g VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

^j HOSPITAL JOSEP TRUETA   (Spain)

^k UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

more..

Author keywords

Distributive shock; Nitric oxide; Nitric oxide scavenger; Pyridoxalated hemoglobin polyoxyethylene; Vasopressors

Indexed keywords

HEMOGLOBIN; NORADRENALIN; POLYOXYETHYLENE; PYRIDOXALATED HEMOGLOBIN POLYOXYETHYLENE; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE; NITRIC OXIDE; PYRIDOXALATED-HEMOGLOBIN-POLYETHYLENE GLYCOL CONJUGATE;

ADULT; AGED; APACHE; ARTICLE; ARTIFICIAL VENTILATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DISTRIBUTIVE SHOCK; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUID RESUSCITATION; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; MULTICENTER STUDY; OPEN STUDY; ORGAN DYSFUNCTION SCORE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VASCULAR DISEASE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; LENGTH OF STAY; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMOGLOBINS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NITRIC OXIDE; POLYETHYLENE GLYCOLS; RESPIRATION, ARTIFICIAL; SHOCK; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84925620537     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000554     Document Type: Article

References (28)

1. Vincent JL, De Backer D: Circulatory shock. N Engl J Med 2013; 369:1726-1734
2. Levy B, Dusang B, Annane D, et al; College Interregional des Réanimateurs du Nord-Est: Cardiovascular response to dopamine and early prediction of outcome in septic shock: A prospective multiple-center study. Crit Care Med 2005; 33:2172-2177
3. Kumar A, Schupp E, Bunnell E, et al: Cardiovascular response to dobutamine stress predicts outcome in severe sepsis and septic shock. Crit Care 2008; 12:R35
4. Brown SM, Lanspa MJ, Jones JP, et al: Survival after shock requiring high-dose vasopressor therapy. Chest 2013; 143:664-671
5. Luckner G, Dünser MW, Jochberger S, et al: Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005; 33:2659-2666
6. Jenkins CR, Gomersall CD, Leung P, et al: Outcome of patients receiving high dose vasopressor therapy: A retrospective cohort study. Anaesth Intensive Care 2009; 37:286-289
7. Dünser MW, Mayr AJ, Ulmer H, et al: Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation 2003; 107:2313-2319
8. Torgersen C, Dünser MW, Wenzel V, et al: Comparing two different arginine vasopressin doses in advanced vasodilatory shock: A randomized, controlled, open-label trial. Intensive Care Med 2010; 36:57-65
9. Russell JA, Walley KR, Singer J, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887
10. Cauwels A: Nitric oxide in shock. Kidney Int 2007; 72:557-565
11. Court O, Kumar A, Parrillo JE, et al: Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 2002; 6:500-508
12. Tsuneyoshi I, Kanmura Y, Yoshimura N: Nitric oxide as a mediator of reduced arterial responsiveness in septic patients. Crit Care Med 1996; 24:1083-1086
13. Levy B, Collin S, Sennoun N, et al: Vascular hyporesponsiveness to vasopressors in septic shock: From bench to bedside. Intensive Care Med 2010; 36:2019-2029
14. Brealey D, Brand M, Hargreaves I, et al: Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360:219-223
15. Dyson A, Bryan NS, Fernandez BO, et al: An integrated approach to assessing nitroso-redox balance in systemic inflammation. Free Radic Biol Med 2011; 51:1137-1145
16. Bakker J, Grover R, McLuckie A, et al; Glaxo Wellcome International Septic Shock Study Group: Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004; 32:1-12
17. López A, Lorente JA, Steingrub J, et al: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30
18. Harbrecht BG: Therapeutic use of nitric oxide scavengers in shock and sepsis. Curr Pharm Des 2006; 12:3543-3549
19. Privalle C, Talarico T, Keng T, et al: Pyridoxalated hemoglobin polyoxyethylene: A nitric oxide scavenger with antioxidant activity for the treatment of nitric oxide-induced shock. Free Radic Biol Med 2000; 28:1507-1517
20. Kinasewitz GT, Privalle CT, Imm A, et al: Multicenter, randomized, placebo-controlled study of the nitric oxide scavenger pyridoxalated hemoglobin polyoxyethylene in distributive shock. Crit Care Med 2008; 36:1999-2007
21. American College of Chest Physicians-Society of Critical Care Medicine: Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
22. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
23. Vincent JL, Moreno R, Takala J et al: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22:707-710
24. Silverman TA, Weiskopf RB; Planning Committee and the Speakers: Hemoglobin-based oxygen carriers: Current status and future directions. Anesthesiology 2009; 111:946-963
25. Ince C: The microcirculation is the motor of sepsis. Crit Care 2005; 9:S13-S19
26. Sloan EP, Koenigsberg M, Gens D, et al: Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: A randomized controlled efficacy trial. JAMA 1999; 282:1857-1864
27. Freilich D, Pearce LB, Pitman A, et al: HBOC-201 vasoactivity in a phase III clinical trial in orthopedic surgery subjects-extrapolation of potential risk for acute trauma trials. J Trauma 2009; 66:365-376
28. Nisoli E, Falcone S, Tonello C, et al: Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals. Proc Natl Acad Sci U S A 2004; 101:16507-16512